Tarpeyo™(budesonide) – New orphan drug approval
On December 15, 2021, the FDA announced the approval of Calliditas Therapeutics’ Tarpeyo (budesonide), to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
Top